The fifth installment of the NEALS webinar series on ALS drug development moderated by Dr. Richard Bedlack from Duke ALS Clinic. This series includes talks on the preclinical development of potential therapies, the regulatory pathway, the science of trials, ethical considerations, the clinical trial site level overview, and the importance of participant engagement.
In this webinar, Dr. Bowser and Dr. Lagier-Tourenne discussed the preclinical development of potential therapies.
